Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank 指定難病告示番号
1 ADH1A 9件: Glycolysis / Gluconeogenesis, Fatty acid degradation, Tyrosine metabolism, Pyruvate metabolism, Retinol metabolism, Metabolism of xenobiotics by cytochrome P450, Drug metabolism - cytochrome P450, Metabolic pathways, Alcoholic liver disease D00707 Fomepizole 1件: 301
2 ADH1B 9件: Glycolysis / Gluconeogenesis, Fatty acid degradation, Tyrosine metabolism, Pyruvate metabolism, Retinol metabolism, Metabolism of xenobiotics by cytochrome P450, Drug metabolism - cytochrome P450, Metabolic pathways, Alcoholic liver disease D00707 Fomepizole 1件: 301
3 ADH1C 9件: Glycolysis / Gluconeogenesis, Fatty acid degradation, Tyrosine metabolism, Pyruvate metabolism, Retinol metabolism, Metabolism of xenobiotics by cytochrome P450, Drug metabolism - cytochrome P450, Metabolic pathways, Alcoholic liver disease D00707 Fomepizole 1件: 301
4 ADORA1 7件: cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00045 Adenosine 3件: 13, 58, 65
5 ADORA1 7件: cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00227 Aminophylline 1件: 63
6 ADORA1 7件: cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00371 Theophylline 2件: 236, 299
7 ADORA1 7件: cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00528 Caffeine 8件: 2, 6, 21, 46, 78, 96, 97, 265
8 ADORA1 7件: cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01453 Caffeine 8件: 2, 6, 21, 46, 78, 96, 97, 265
9 ADORA1 7件: cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D02769 Adenosine phosphate 1件: 46
10 ADORA1 7件: cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D06103 Theophylline 2件: 236, 299
11 ADORA2A 7件: Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D00045 Adenosine 3件: 13, 58, 65
12 ADORA2A 7件: Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D00528 Caffeine 8件: 2, 6, 21, 46, 78, 96, 97, 265
13 ADORA2A 7件: Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D01453 Caffeine 8件: 2, 6, 21, 46, 78, 96, 97, 265
14 ADORA2A 7件: Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D02769 Adenosine phosphate 1件: 46
15 ADORA2A 7件: Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D04641 Istradefylline 1件: 6
16 ADORA2A 7件: Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D05711 Regadenoson 1件: 58
17 ADORA2A 7件: Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D09717 Preladenant 1件: 6
18 ADORA2A 7件: Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D10174 Tozadenant 1件: 6
19 ADORA2A 7件: Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D12568 Regadenoson 1件: 58
20 ADORA2B 5件: Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism D00045 Adenosine 3件: 13, 58, 65
21 ADORA2B 5件: Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism D00227 Aminophylline 1件: 63
22 ADORA2B 5件: Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism D00371 Theophylline 2件: 236, 299
23 ADORA2B 5件: Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism D02769 Adenosine phosphate 1件: 46
24 ADORA2B 5件: Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism D06103 Theophylline 2件: 236, 299
25 ADORA3 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D00045 Adenosine 3件: 13, 58, 65
26 ADORA3 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D02769 Adenosine phosphate 1件: 46
27 ADORA3 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10971 Piclidenoson 1件: 46
28 ADRA1D 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00076 Norepinephrine 2件: 22, 296
29 ADRA1D 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine 3件: 46, 70, 96
30 ADRA1D 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00124 Ephedrine 1件: 11
31 ADRA1D 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00255 Carvedilol 4件: 57, 86, 113, 210
32 ADRA1D 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00454 Olanzapine 2件: 2, 8
33 ADRA1D 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa 5件: 5, 6, 17, 169, 170
34 ADRA1D 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin 1件: 6
35 ADRA1D 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02910 Amiodarone 2件: 28, 127
36 ADRA1D 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D07874 Doxazosin 2件: 57, 67
37 ADRA1D 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08207 Methylergometrine 1件: 280
38 ADRA1D 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine 3件: 6, 17, 58
39 ADRA1D 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08365 Phenylephrine 1件: 22
40 ADRA1D 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08449 Pseudoephedrine 1件: 17
41 ADRA1D 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08560 Tamsulosin 1件: 13
42 ADRA1D 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin 1件: 6
43 ADRA1B 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00076 Norepinephrine 2件: 22, 296
44 ADRA1B 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine 3件: 46, 70, 96
45 ADRA1B 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00124 Ephedrine 1件: 11
46 ADRA1B 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00255 Carvedilol 4件: 57, 86, 113, 210
47 ADRA1B 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00454 Olanzapine 2件: 2, 8
48 ADRA1B 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa 5件: 5, 6, 17, 169, 170
49 ADRA1B 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin 1件: 6
50 ADRA1B 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02910 Amiodarone 2件: 28, 127
51 ADRA1B 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D07874 Doxazosin 2件: 57, 67
52 ADRA1B 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08207 Methylergometrine 1件: 280
53 ADRA1B 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine 3件: 6, 17, 58
54 ADRA1B 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08365 Phenylephrine 1件: 22
55 ADRA1B 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08449 Pseudoephedrine 1件: 17
56 ADRA1B 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08560 Tamsulosin 1件: 13
57 ADRA1B 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin 1件: 6
58 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00076 Norepinephrine 2件: 22, 296
59 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine 3件: 46, 70, 96
60 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00124 Ephedrine 1件: 11
61 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00255 Carvedilol 4件: 57, 86, 113, 210
62 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00454 Olanzapine 2件: 2, 8
63 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa 5件: 5, 6, 17, 169, 170
64 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01965 Silodosin 2件: 6, 13
65 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin 1件: 6
66 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02910 Amiodarone 2件: 28, 127
67 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D07124 Alfuzosin 1件: 13
68 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D07874 Doxazosin 2件: 57, 67
69 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08207 Methylergometrine 1件: 280
70 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine 3件: 6, 17, 58
71 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08365 Phenylephrine 1件: 22
72 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08449 Pseudoephedrine 1件: 17
73 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08560 Tamsulosin 1件: 13
74 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin 1件: 6
75 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00076 Norepinephrine 2件: 22, 296
76 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00095 Epinephrine 3件: 46, 70, 96
77 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00124 Ephedrine 1件: 11
78 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00270 Chlorpromazine 1件: 254
79 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00281 Clonidine 4件: 6, 65, 70, 78
80 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00283 Clozapine 1件: 6
81 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine 14件: 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280
82 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00560 Pimozide 1件: 2
83 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01277 Droxidopa 5件: 5, 6, 17, 169, 170
84 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02349 Dipivefrin 1件: 6
85 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04375 Guanabenz 2件: 2, 13
86 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07461 Apraclonidine 1件: 11
87 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07540 Brimonidine 2件: 13, 90
88 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08031 Guanfacine 1件: 193
89 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08207 Methylergometrine 1件: 280
90 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08449 Pseudoephedrine 1件: 17
91 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08482 Rilmenidine 1件: 8
92 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08611 Tizanidine 1件: 13
93 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08685 Yohimbine 1件: 6
94 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00076 Norepinephrine 2件: 22, 296
95 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00095 Epinephrine 3件: 46, 70, 96
96 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00124 Ephedrine 1件: 11
97 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00270 Chlorpromazine 1件: 254
98 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00281 Clonidine 4件: 6, 65, 70, 78
99 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00283 Clozapine 1件: 6
100 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine 14件: 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280
101 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01277 Droxidopa 5件: 5, 6, 17, 169, 170
102 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02349 Dipivefrin 1件: 6
103 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04375 Guanabenz 2件: 2, 13
104 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07461 Apraclonidine 1件: 11
105 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07540 Brimonidine 2件: 13, 90
106 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08207 Methylergometrine 1件: 280
107 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08449 Pseudoephedrine 1件: 17
108 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08482 Rilmenidine 1件: 8
109 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08611 Tizanidine 1件: 13
110 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08685 Yohimbine 1件: 6
111 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00076 Norepinephrine 2件: 22, 296
112 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00095 Epinephrine 3件: 46, 70, 96
113 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00124 Ephedrine 1件: 11
114 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00270 Chlorpromazine 1件: 254
115 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00281 Clonidine 4件: 6, 65, 70, 78
116 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00283 Clozapine 1件: 6
117 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine 14件: 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280
118 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01277 Droxidopa 5件: 5, 6, 17, 169, 170
119 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02349 Dipivefrin 1件: 6
120 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04375 Guanabenz 2件: 2, 13
121 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07461 Apraclonidine 1件: 11
122 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07540 Brimonidine 2件: 13, 90
123 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08207 Methylergometrine 1件: 280
124 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08449 Pseudoephedrine 1件: 17
125 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08482 Rilmenidine 1件: 8
126 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08611 Tizanidine 1件: 13
127 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08685 Yohimbine 1件: 6
128 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00076 Norepinephrine 2件: 22, 296
129 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00095 Epinephrine 3件: 46, 70, 96
130 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00124 Ephedrine 1件: 11
131 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00235 Atenolol 1件: 167
132 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00255 Carvedilol 4件: 57, 86, 113, 210
133 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00378 Timolol 2件: 157, 227
134 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00432 Nadolol 1件: 6
135 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D01277 Droxidopa 5件: 5, 6, 17, 169, 170
136 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02342 Bisoprolol 4件: 58, 67, 86, 113
137 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02349 Dipivefrin 1件: 6
138 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02358 Metoprolol 6件: 17, 57, 58, 113, 193, 226
139 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02910 Amiodarone 2件: 28, 127
140 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D03879 Dobutamine 4件: 57, 58, 86, 215
141 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D05127 Nebivolol 4件: 17, 85, 113, 167
142 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D07660 Celiprolol 1件: 168
143 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D07916 Esmolol 1件: 58
144 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D08443 Propranolol 6件: 6, 158, 167, 227, 278, 296
145 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D08449 Pseudoephedrine 1件: 17
146 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D08600 Timolol 2件: 157, 227
147 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00076 Norepinephrine 2件: 22, 296
148 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00095 Epinephrine 3件: 46, 70, 96
149 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00124 Ephedrine 1件: 11
150 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00255 Carvedilol 4件: 57, 86, 113, 210
151 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00378 Timolol 2件: 157, 227
152 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00432 Nadolol 1件: 6
153 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D01277 Droxidopa 5件: 5, 6, 17, 169, 170
154 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02147 Salbutamol 12件: 3, 11, 12, 13, 49, 85, 86, 89, 111, 113, 256, 299
155 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02151 Tulobuterol 1件: 6
156 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02349 Dipivefrin 1件: 6
157 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05792 Salmeterol 1件: 299
158 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D07713 Clenbuterol 5件: 1, 2, 6, 13, 256
159 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D07990 Formoterol 3件: 85, 228, 299
160 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08092 Isoxsuprine 1件: 13
161 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08124 Levosalbutamol 1件: 49
162 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08443 Propranolol 6件: 6, 158, 167, 227, 278, 296
163 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08449 Pseudoephedrine 1件: 17
164 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08570 Terbutaline 1件: 118
165 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08600 Timolol 2件: 157, 227
166 ADRB3 8件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00076 Norepinephrine 2件: 22, 296
167 ADRB3 8件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00095 Epinephrine 3件: 46, 70, 96
168 ADRB3 8件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00124 Ephedrine 1件: 11
169 ADRB3 8件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D01277 Droxidopa 5件: 5, 6, 17, 169, 170
170 ADRB3 8件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02349 Dipivefrin 1件: 6
171 ADRB3 8件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08443 Propranolol 6件: 6, 158, 167, 227, 278, 296
172 ADRB3 8件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08449 Pseudoephedrine 1件: 17
173 ADRB3 8件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D09535 Mirabegron 4件: 6, 13, 53, 226
174 ACE 6件: Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D00251 Captopril 8件: 6, 17, 46, 86, 96, 97, 107, 271
175 ACE 6件: Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D00362 Lisinopril 7件: 19, 46, 49, 66, 67, 113, 222
176 ACE 6件: Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D00421 Ramipril 7件: 46, 49, 66, 67, 113, 218, 257
177 ACE 6件: Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D01069 Cilazapril 1件: 66
178 ACE 6件: Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D03752 Quinapril 1件: 19
179 ACE 6件: Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D03753 Perindopril 4件: 58, 113, 167, 222
180 ACE 6件: Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D07499 Benazepril 4件: 49, 57, 218, 224
181 ACE 6件: Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D07699 Cilazapril 1件: 66
182 ACE 6件: Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D07892 Enalapril 6件: 19, 46, 66, 113, 210, 222
183 ACE 6件: Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D08068 Imidapril 1件: 67
184 ACE 6件: Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D08131 Lisinopril 7件: 19, 46, 49, 66, 67, 113, 222
185 ACE 6件: Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D08225 Moexipril 1件: 93
186 AGTR1 16件: Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00150 Angiotensin II 7件: 17, 19, 46, 66, 86, 222, 224
187 AGTR1 16件: Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00400 Valsartan 7件: 57, 58, 66, 75, 218, 222, 224
188 AGTR1 16件: Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00522 Candesartan 2件: 58, 67
189 AGTR1 16件: Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00523 Irbesartan 4件: 66, 167, 168, 222
190 AGTR1 16件: Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00626 Candesartan cilexetil 1件: 67
191 AGTR1 16件: Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00627 Telmisartan 2件: 66, 67
192 AGTR1 16件: Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D02014 Angiotensin II 7件: 17, 19, 46, 66, 86, 222, 224
193 AGTR1 16件: Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D08146 Losartan 17件: 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299
194 AGTR1 16件: Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D11776 Sparsentan 3件: 66, 218, 222
195 AGTR2 3件: Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Renin-angiotensin system D00150 Angiotensin II 7件: 17, 19, 46, 66, 86, 222, 224
196 AGTR2 3件: Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Renin-angiotensin system D02014 Angiotensin II 7件: 17, 19, 46, 66, 86, 222, 224
197 ABAT 7件: Alanine, aspartate and glutamate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism, Propanoate metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse D00399 Valproic acid 14件: 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256
198 ABAT 7件: Alanine, aspartate and glutamate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism, Propanoate metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse D00535 Vigabatrin 2件: 145, 158
199 ALAS1 4件: Glycine, serine and threonine metabolism, Porphyrin metabolism, Metabolic pathways, Biosynthesis of cofactors D10003 Hemin 1件: 254
200 ALAS1 4件: Glycine, serine and threonine metabolism, Porphyrin metabolism, Metabolic pathways, Biosynthesis of cofactors D11702 Givosiran 1件: 254
201 ALAS2 4件: Glycine, serine and threonine metabolism, Porphyrin metabolism, Metabolic pathways, Biosynthesis of cofactors D10003 Hemin 1件: 254
202 ABCD1 2件: ABC transporters, Peroxisome D12150 Elivaldogene autotemcel 1件: 20
203 ALK 3件: Pathways in cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09731 Crizotinib 1件: 34
204 ALK 3件: Pathways in cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10866 Brigatinib 1件: 34
205 ALOX5 6件: Arachidonic acid metabolism, Metabolic pathways, Fc epsilon RI signaling pathway, Serotonergic synapse, Ovarian steroidogenesis, Toxoplasmosis D00414 Zileuton 3件: 85, 160, 164
206 ALOX5 6件: Arachidonic acid metabolism, Metabolic pathways, Fc epsilon RI signaling pathway, Serotonergic synapse, Ovarian steroidogenesis, Toxoplasmosis D01773 Oxatomide 1件: 113
207 ALPL 4件: Thiamine metabolism, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors D10595 Asfotase alfa 1件: 172
208 ABL1 11件: ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis D03252 Bosutinib 2件: 2, 67
209 ABL1 11件: ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis D03658 Dasatinib 2件: 51, 85
210 ABL1 11件: ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis D06414 Dasatinib 2件: 51, 85
211 ABL1 11件: ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis D08066 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
212 ABL1 11件: ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis D08953 Nilotinib 5件: 6, 8, 34, 51, 86
213 ABL1 11件: ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis D09664 Saracatinib 3件: 6, 89, 272
214 ANGPTL3 1件: Cholesterol metabolism D11753 Evinacumab 1件: 79
215 AMY2A 5件: Starch and sucrose metabolism, Metabolic pathways, Salivary secretion, Pancreatic secretion, Carbohydrate digestion and absorption D00216 Acarbose 1件: 298
216 AMY2B 5件: Starch and sucrose metabolism, Metabolic pathways, Salivary secretion, Pancreatic secretion, Carbohydrate digestion and absorption D00216 Acarbose 1件: 298
217 ANPEP 4件: Glutathione metabolism, Metabolic pathways, Renin-angiotensin system, Hematopoietic cell lineage D00087 Ubenimex 1件: 86
218 APCS - D11464 Miridesap 1件: 28
219 APCS - D11471 Dezamizumab 1件: 28
220 APOC3 2件: PPAR signaling pathway, Cholesterol metabolism D11648 Volanesorsen 1件: 265
221 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00075 Testosterone 8件: 1, 2, 3, 13, 60, 76, 78, 113
222 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00289 Danazol 5件: 60, 63, 64, 65, 285
223 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00444 Stanozolol 1件: 60
224 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00462 Oxandrolone 2件: 211, 285
225 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00586 Flutamide 1件: 81
226 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00955 Nandrolone decanoate 2件: 60, 85
227 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00958 Testosterone enanthate 1件: 113
228 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00959 Testosterone propionate 1件: 113
229 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D03338 Calusterone 1件: 2
230 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D06087 Testosterone undecanoate 2件: 13, 60
231 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D08250 Nandrolone 2件: 60, 85
232 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D08409 Prasterone 6件: 49, 53, 83, 86, 96, 113
233 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D08573 Testosterone decanoate 1件: 113
234 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D08574 Testosterone phenylpropionate 1件: 113
235 ARSB 3件: Glycosaminoglycan degradation, Metabolic pathways, Lysosome D06565 Galsulfase 1件: 19
236 ACHE 2件: Glycerophospholipid metabolism, Cholinergic synapse D03822 Rivastigmine 3件: 5, 6, 13
237 ACHE 2件: Glycerophospholipid metabolism, Cholinergic synapse D04292 Galantamine 2件: 6, 127
238 ACHE 2件: Glycerophospholipid metabolism, Cholinergic synapse D07869 Donepezil 9件: 5, 6, 13, 46, 78, 124, 127, 156, 206
239 ACHE 2件: Glycerophospholipid metabolism, Cholinergic synapse D08555 Tacrine 2件: 46, 271
240 ACHE 2件: Glycerophospholipid metabolism, Cholinergic synapse D09917 Latrepirdine 1件: 8
241 ATP1A1 18件: cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption D00297 Digitoxin 1件: 299
242 ATP1A1 18件: cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption D00298 Digoxin 3件: 8, 46, 210
243 ATP1A2 18件: cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption D00297 Digitoxin 1件: 299
244 ATP1A2 18件: cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption D00298 Digoxin 3件: 8, 46, 210
245 ATP1A3 18件: cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption D00297 Digitoxin 1件: 299
246 ATP1A3 18件: cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption D00298 Digoxin 3件: 8, 46, 210
247 ATP1A4 18件: cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption D00297 Digitoxin 1件: 299
248 ATP1A4 18件: cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption D00298 Digoxin 3件: 8, 46, 210
249 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D00355 Lansoprazole 7件: 63, 71, 85, 98, 166, 222, 299
250 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D00455 Omeprazole 14件: 6, 8, 21, 46, 51, 85, 96, 97, 225, 271, 282, 294, 298, 299
251 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05353 Pantoprazole 2件: 13, 65
252 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D07917 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
253 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D08463 Rabeprazole 2件: 2, 51
254 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D08903 Dexlansoprazole 1件: 98
255 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D11784 Vonoprazan 2件: 63, 98
256 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D00355 Lansoprazole 7件: 63, 71, 85, 98, 166, 222, 299
257 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D00455 Omeprazole 14件: 6, 8, 21, 46, 51, 85, 96, 97, 225, 271, 282, 294, 298, 299
258 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05353 Pantoprazole 2件: 13, 65
259 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D07917 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
260 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D08463 Rabeprazole 2件: 2, 51
261 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D08903 Dexlansoprazole 1件: 98
262 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D11784 Vonoprazan 2件: 63, 98
263 APH1A 2件: Notch signaling pathway, Alzheimer disease D09010 Tarenflurbil 1件: 13
264 AVPR1A 4件: Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D00101 Vasopressin 1件: 210
265 AVPR1A 4件: Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D06672 Terlipressin 1件: 299
266 AVPR1A 4件: Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D07748 Conivaptan 1件: 86
267 AVPR1B 4件: Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D00101 Vasopressin 1件: 210
268 AVPR1B 4件: Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D06672 Terlipressin 1件: 299
269 AVPR2 3件: Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D00101 Vasopressin 1件: 210
270 AVPR2 3件: Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D00291 Desmopressin 6件: 6, 64, 72, 75, 225, 288
271 AVPR2 3件: Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D01213 Tolvaptan 4件: 67, 72, 86, 225
272 AVPR2 3件: Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D04752 Lixivaptan 1件: 67
273 AVPR2 3件: Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D06672 Terlipressin 1件: 299
274 AVPR2 3件: Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D07748 Conivaptan 1件: 86
275 AXL 1件: EGFR tyrosine kinase inhibitor resistance D10062 Cabozantinib 1件: 34
276 ABCC8 3件: ABC transporters, Insulin secretion, Type II diabetes mellitus D00294 Diazoxide 2件: 13, 193
277 ABCC8 3件: ABC transporters, Insulin secretion, Type II diabetes mellitus D00418 Minoxidil 1件: 179
278 ABCC8 3件: ABC transporters, Insulin secretion, Type II diabetes mellitus D00594 Repaglinide 4件: 6, 21, 46, 299
279 ADAM17 4件: Notch signaling pathway, Alzheimer disease, Epithelial cell signaling in Helicobacter pylori infection, Coronavirus disease - COVID-19 D08859 Apratastat 1件: 46
280 ALDH5A1 3件: Alanine, aspartate and glutamate metabolism, Butanoate metabolism, Metabolic pathways D00399 Valproic acid 14件: 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256
281 AOC3 5件: Glycine, serine and threonine metabolism, Tyrosine metabolism, Phenylalanine metabolism, beta-Alanine metabolism, Metabolic pathways D08044 Hydralazine 1件: 67
282 ACVR2A 4件: Cytokine-cytokine receptor interaction, TGF-beta signaling pathway, Signaling pathways regulating pluripotency of stem cells, Fluid shear stress and atherosclerosis D09670 Sotatercept 2件: 86, 284
283 ACVR2A 4件: Cytokine-cytokine receptor interaction, TGF-beta signaling pathway, Signaling pathways regulating pluripotency of stem cells, Fluid shear stress and atherosclerosis D10620 Bimagrumab 1件: 15
284 ACVR2B 4件: Cytokine-cytokine receptor interaction, TGF-beta signaling pathway, Signaling pathways regulating pluripotency of stem cells, Fluid shear stress and atherosclerosis D10620 Bimagrumab 1件: 15
285 ACVR2B 4件: Cytokine-cytokine receptor interaction, TGF-beta signaling pathway, Signaling pathways regulating pluripotency of stem cells, Fluid shear stress and atherosclerosis D11701 Luspatercept 1件: 60